Literature DB >> 28634834

Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome.

Giuliana Galassi1, Francesca Testa2, Francesca Bianchi3, Gianni Cappelli2, Annalisa Chiari3.   

Abstract

Entities:  

Year:  2017        PMID： 28634834      PMCID： PMC5694402          DOI： 10.1007/s13730-017-0264-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN： 2192-4449


× No keyword cloud information.
  5 in total

1.  Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.

Authors:  Abraham C J Stork; Nicolette C Notermans; Alexander F J E Vrancken; David R Cornblath; W-Ludo van der Pol
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494

2.  Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.

Authors:  Fabrizia Terenghi; Gianluca Ardolino; Eduardo Nobile-Orazio
Journal:  J Peripher Nerv Syst       Date:  2007-06       Impact factor: 3.494

3.  Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following rituximab.

Authors:  Michael D Weiss; Pamela Becker
Journal:  Muscle Nerve       Date:  2014-03       Impact factor: 3.217

4.  Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.

Authors:  Ruxandra Iancu Ferfoglia; Raquel Guimarães-Costa; Karine Viala; Lucile Musset; Jean Neil; Benoit Marin; Jean-Marc Léger
Journal:  J Peripher Nerv Syst       Date:  2016-03       Impact factor: 3.494

Review 5.  Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.

Authors:  Paolo Cravedi
Journal:  Nephron       Date:  2016-09-28       Impact factor: 2.847
  5 in total
  2 in total

1.  Dermatomyositis-Induced Rhabdomyolysis With Features of Necrotizing Myopathy and Acute Inflammatory Demyelinating Polyneuropathy in an Epstein-Barr Virus Infected Patient.

Authors:  Ammar Haikal; Swati Govil; Arsany Anis; Jenna Guma
Journal:  Cureus       Date:  2020-12-14

2.  Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study

Authors:  Mehmet Taşdemir; Nur Canpolat; Nurdan Yıldız; Gül Özçelik; Meryem Benzer; Seha Kamil Saygılı; Emine Neşe Özkayin; Özde Nisa Türkkan; Ayşe Balat; Cengiz Candan; Mehtap Çelakıl; Sevgi Yavuz; Nurver Akıncı; Nilüfer Göknar; Cihangir Akgün; Sebahat Tülpar; Harika Alpay; Fatma Lale Sever; İlmay Bilge
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.